Over recent years there has been a significant increase in effort in developing effective therapeutic strategies to target KRAS mutant tumours either through direct targeting of KRAS or indirect targeting of the RAS-MEK-ERK signalling pathway.33 Direct pharmacological inhibition of RAS has proved challenging due to the high affinity of RAS for GTP. The gene discussed is MAP2K7; the disease is neoplasm.